Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

New long-term data from the Phase III FLAURA2 trial confirm that Tagrisso combined with chemotherapy delivers a significant overall survival benefit over monotherapy in patients with advanced ...

TAGRISSO demonstrated efficacy in patients with measurable central nervous system (CNS) lesions at baseline. March 31, 2017 07:00 AM Eastern Daylight Time.

LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFR m NSCLC after chemoradiotherapy. SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFR m NSCLC with high levels of ...

TAGRISSO is approved as monotherapy in more than 100 countries including in the US, EU, China and Japan. These include for 1st-line treatment of patients with locally advanced or metastatic EGFRm ...

Tagrisso appears to short-circuit this excessive growth. The new trial involved 682 patients with stages IB, II or IIIA non-small cell lung cancers (NSCLC). About 85% of lung cancers are NSCLCs.

AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically ...